Table 5.
Multiple regression model in VitD deficient and VitD non-deficient patients.
| 25 (OH)D-FF | Bioavailable 25 (OH)D-FF | Free 25 (OH)D-FF | |||||||
|---|---|---|---|---|---|---|---|---|---|
| VitD metabolite | OR | 95% CI | p value | OR | 95% CI | p value | OR | 95% CI | p value |
| 1.15 | 1.02–1.30 | 0.017 | 7.57 | 2.21–25.96 | 0.001 | 0.0 | 0.0–0.0 | 0.009 | |
| BMI | 1.01 | 0.92–1.12 | 0.705 | 1.01 | 0.92–1.12 | 0.797 | 0.98 | 0.89–1.08 | 0.695 |
| Age | 0.93 | 0.87–1.00 | 0.063 | 0.93 | 0.87–1.00 | 0.095 | 1.06 | 0.99–1.14 | 0.067 |
| AMH | 1.01 | 0.83–1.23 | 0.865 | 1.01 | 0.83–1.23 | 0.947 | 0.99 | 0.81–1.21 | 0.924 |
| Status VitD | 33.36 | 3.7–300.76 | 0.002 | 50.34 | 6.94–364.96 | < 0.001 | 0.02 | 0.002–0.203 | < 0.001 |
| VitD metabolite-status VitD | 0.84 | 0.75–0.95 | 0.009 | 0.10 | 0.03–0.36 | < 0.001 | NE | NE -NE | < 0.001 |
Reference group is VitD non-deficient, modelling for a euploid embryo.
Results are expressed as OR, Odds Ratio; 95% CI, confidence interval and p values.
BMI, body mass index; AMH, anti-Müllerian hormone.
Status VitD: VitD status of the patient, VitD non-deficient compared to VitD deficient.
VitD metabolite-status VitD: Interaction between each VitD metabolite 25(OH)-D-FF, bioavailable 25(OH)-D-FF and free 25(OH)-D-FF and the status of the patient (VitD non-deficient as a reference).